BR112015009128A2 - inibidores de protease flavivirus - Google Patents

inibidores de protease flavivirus

Info

Publication number
BR112015009128A2
BR112015009128A2 BR112015009128A BR112015009128A BR112015009128A2 BR 112015009128 A2 BR112015009128 A2 BR 112015009128A2 BR 112015009128 A BR112015009128 A BR 112015009128A BR 112015009128 A BR112015009128 A BR 112015009128A BR 112015009128 A2 BR112015009128 A2 BR 112015009128A2
Authority
BR
Brazil
Prior art keywords
flavivirus
methods
protease inhibitors
protease
treating
Prior art date
Application number
BR112015009128A
Other languages
English (en)
Inventor
Manzano Mark
Padmanabhan Radhakrishnan
Teramoto Tadahisa
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of BR112015009128A2 publication Critical patent/BR112015009128A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo inibidores de protease flavivirus métodos de tratamento ou prevenção de uma infecção em um indivíduo flavivirus são fornecidos. os métodos compreendem a administração ao indivíduo de uma quantidade terapeuticamente eficaz de um inibidor de flavivirus, por exemplo, um inibidor da protease flavivirus. estes métodos são úteis no tratamento e/ou prevenção de infecções flavivirus, tal como, por exemplo, vírus de nilo ocidental, vírus da dengue, e vírus da encefalite japonesa. os métodos de inibição de uma protease em uma célula flavivirus são também fornecidos.
BR112015009128A 2012-10-23 2013-10-23 inibidores de protease flavivirus BR112015009128A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717221P 2012-10-23 2012-10-23
PCT/US2013/066380 WO2014066502A2 (en) 2012-10-23 2013-10-23 Flavivirus protease inhibitors

Publications (1)

Publication Number Publication Date
BR112015009128A2 true BR112015009128A2 (pt) 2017-07-04

Family

ID=50545466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009128A BR112015009128A2 (pt) 2012-10-23 2013-10-23 inibidores de protease flavivirus

Country Status (4)

Country Link
US (1) US10471082B2 (pt)
BR (1) BR112015009128A2 (pt)
MX (1) MX2015005098A (pt)
WO (1) WO2014066502A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014253607B2 (en) * 2013-04-16 2019-05-16 Monash University Method of viral inhibition
CN110898043B (zh) * 2019-10-25 2023-01-17 南方医科大学 (3,4-二羟基-5-硝基苯基)-(4-甲基苯基)甲酮的医药用途
CN113876755A (zh) * 2021-09-23 2022-01-04 天津国际生物医药联合研究院 阿伐麦布在抗圣路易斯脑炎病毒感染中的潜在应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595923A1 (en) * 2005-02-07 2006-12-14 Irm Llc Methods for identifying compounds that inhibit hiv infection
BRPI0815557A2 (pt) 2007-08-13 2015-02-18 Metabasis Therapeuticas Inc Atividaores de glicocinase
WO2010039538A2 (en) * 2008-09-23 2010-04-08 Georgetown University Flavivirus inhibitors and methods for their use
CA2753421A1 (en) * 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2010141738A2 (en) * 2009-06-03 2010-12-09 President And Fellows Of Harvard College Compositions and method for inhibiting tumor growth

Also Published As

Publication number Publication date
WO2014066502A2 (en) 2014-05-01
US20150272976A1 (en) 2015-10-01
WO2014066502A3 (en) 2014-07-03
MX2015005098A (es) 2015-09-25
US10471082B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
UY33897A (es) Inhibidores del virus de la hepatitis c
BR112014020345A8 (pt) medicamentos antivirais para o tratamento da infecção por arenavírus
BR112013003101A2 (pt) inibidores do vírus da hepatite c
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
WO2010039538A3 (en) Flavivirus inhibitors and methods for their use
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
MX337936B (es) Compuestos inhibidores del virus de la hepatitis c.
BR112014021065A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor
TR201908247T4 (tr) Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
IN2014CN03113A (pt)
GB201208879D0 (en) Therapeutic for treating Clostridium difficile infection
WO2013106689A8 (en) Hcv ns3 protease inhibitors
BR112014021068A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
IN2014CN00572A (pt)
BR112014008616A2 (pt) compostos antivirais
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
BR112015009128A2 (pt) inibidores de protease flavivirus
BR112015026243A2 (pt) método de inibição viral
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08G Application fees: restoration
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2600 DE 03-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.